Welcome to our dedicated page for Charlie S Holdin news (Ticker: CHUC), a resource for investors and traders seeking the latest updates and insights on Charlie S Holdin stock.
Charlie’s Holdings, Inc. reports developments in premium vapor products and electronic nicotine delivery systems. The company sells product lines including SBX, Pachamama and PACHA through distributors, specialty retailers and online resellers, with operating activity tied to Charlie’s Chalk Dust, LLC.
Recurring updates center on FDA Premarket Tobacco Product Applications, state vapor-product requirements, age-verification technology for device activation, product-line distribution, trade-show participation, financial results and capital actions such as private placements and debt forgiveness.
Charlie's Holdings, Inc. (OTCQB:CHUC) announced that a majority of its preferred shareholders consented to automatic conversion of "Preferred A Shares" into common stock upon uplisting to national securities exchanges. The decision also allows increasing permitted indebtedness from $2.5 million to $6.0 million to secure additional working capital. The company has made significant improvements in product offerings, sales revenue, and plans to share new intellectual property with the FDA. Management views these moves as critical steps toward achieving their long-term goal of a national securities exchange uplisting.
Charlie's Holdings (OTCQB:CHUC) is pioneering patented age-gating technology aimed at controlling access to flavored e-cigarettes. This initiative, led by expert Dr. Edward Carmines, seeks FDA recognition as a 'product of merit' to legally market these products in the $7 billion U.S. market while preventing underage access. Engaging Fish & Richardson for patent development, Charlie's aims to align with FDA regulations, positioning its PACHA™ disposable e-cigarettes as potential market leaders. The push comes at a time of heightened scrutiny on e-cigarette sales, following Juul Labs' $1.2 billion settlement related to youth vaping issues.
Charlie's Holdings (OTCQB: CHUC) reported strong financial results for the nine months ending September 30, 2022, with a 46% revenue growth to $21.9 million. Gross profit also rose 16% to $9.2 million, while operating expenses decreased as a percentage of revenue from 53% to 43%. However, net income fell to $0.3 million from $2.7 million, reflecting lower gains in derivative liabilities. The company announced the national launch of PINWEEL, a new alternative cannabis product line derived from hemp, aiming to reduce regulatory risks associated with its nicotine products.
Charlie's Holdings, Inc. (OTCQB: CHUC) has announced the national launch of its new alternative cannabis brand, PINWEEL, made from 100% hemp extract. The product line, featuring proprietary blends of Delta 8, Delta 11, THC-O, THC-P, and HHC, caters to adult consumers seeking alternatives to traditional cannabis and alcohol.
The alternative cannabis market is rapidly growing, and Charlie's has reported that over 90% of its initial inventory has been reserved in pre-orders. The company plans to introduce additional flavors and blends in 2023.
Charlie's Holdings, Inc. (OTCQB:CHUC) is set to achieve its best year ever in 2022, according to President Henry Sicignano III. The company will participate in two major investor conferences: the Dawson James Securities Small Cap Growth Conference on October 12, 2022, and the LD Micro Main Event on October 25, 2022. Sicignano highlighted the ongoing FDA reviews of their e-liquids and impressive growth in their nicotine-based vapor products and cannabis product categories. Investors can arrange one-on-one meetings at both events.
Charlie's Holdings, Inc. (OTCQB:CHUC) reported a 58% increase in revenue to $15.5 million for the first half of 2022, driven by strong sales of nicotine-based vapor products. The company also noted a 36% revenue growth to $7.4 million for Q2 2022, although net loss reached $0.6 million compared to net income of $19.8 million in Q2 2021. Operating expenses decreased as a percentage of revenue from 56% to 43%. Charlie's PMTAs for its products are under review by the FDA, positioning the company in a favorable regulatory position.
Charlie's Holdings (OTCQB:CHUC) reported a significant 85% revenue increase to $8.1 million in Q1 2022, alongside a 51% rise in gross profit to $3.6 million. The company achieved a net income of $0.7 million, a notable recovery from a $20.1 million loss in Q1 2021. Key advancements included the appointment of Edward Carmines, Ph.D. to the board and successful PMTA submissions for its product lines, maintaining compliance with evolving FDA regulations on nicotine. The company aims for ongoing growth and stability in a challenging regulatory landscape.
Charlie's Holdings, Inc. (OTCQB:CHUC) reported significant financial growth for 2021, with a 29% revenue increase to $21.5 million and a net income of $4.8 million, up from a net loss of $7.2 million the previous year. Key highlights include a 53% revenue growth in Q4, operating expenses down 34%, and successful PMTA submissions still viable with the FDA. The company aims to expand into hemp-derived products and international markets while strengthening its PMTA strategy, led by new Board member, PMTA expert Edward Carmines.
Charlie's Holdings (OTCQB: CHUC) appointed Dr. Edward Carmines to its Board of Directors. Carmines, a regulatory expert, has experience with the FDA, including successful PMTA and MRTPA applications. This appointment is timely, as the FDA has issued numerous marketing denial orders affecting e-cigarette products. The leadership hopes Carmines' expertise will enhance the Company's existing PMTAs currently under review. His previous successes include being the architect behind a notable MRTP marketing order at 22nd Century Group.
Charlie's Holdings, Inc. (OTCQB:CHUC) reported its Q3 2021 financial results, showcasing a 34% increase in revenue to $5.2 million compared to Q3 2020. The company's gross profit rose 31% to $2.9 million, while operating income improved significantly to $0.4 million, reversing a loss of $0.9 million last year. Net income surged to $3.1 million, up from a loss of $6.8 million, aided by a gain in fair value of derivative liabilities. Management highlighted ongoing progress towards uplisting and confidence in PMTA submissions.